MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1053/j.jvca.2023.04.011

Медицинская библиотека · Journal of cardiothoracic and vascular anesthesia · 2023

A Multimodal Cardioprotection Strategy During Cardiac Surgery: The ProCCard Study.

Chiari Pascal, Desebbe Olivier, Durand Michel, Fischer Marc-Olivier, Lena-Quintard Diane, Palao Jean-Charles, Samson Géraldine, Varillon Yvonne, Vaz Bernadette, Joseph Pierre, Ferraris Arnaud, Jacquet-Lagreze Matthias, Pozzi Matteo, Maucort-Boulch Delphine, Ovize Michel, Bidaux Gabriel, Mewton Nathan, Fellahi Jean-Luc, ProCCard Trial Investigators

Рандомизированное исследованиеМногоцентровое исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

OBJECTIVE

The ProCCard study tested whether combining several cardioprotective interventions would reduce the myocardial and other biological and clinical damage in patients undergoing cardiac surgery.

DESIGN

Prospective, randomized, controlled trial.

SETTING

Multicenter tertiary care hospitals.

PARTICIPANTS

210 patients scheduled to undergo aortic valve surgery.

INTERVENTIONS: A control group (standard of care) was compared to a treated group combining five perioperative cardioprotective techniques: anesthesia with sevoflurane, remote ischemic preconditioning, close intraoperative blood glucose control, moderate respiratory acidosis (pH 7.30) just before aortic unclamping (concept of the "pH paradox"), and gentle reperfusion just after aortic unclamping.

MEASUREMENTS AND MAIN

RESULTS

The primary outcome was the postoperative 72-h area under the curve (AUC) for high-sensitivity cardiac troponin I (hsTnI). Secondary endpoints were biological markers and clinical events occurring during the 30 postoperative days and the prespecified subgroup analyses. The linear relationship between the 72-h AUC for hsTnI and aortic clamping time, significant in both groups (p < 0.0001), was not modified by the treatment (p = 0.57). The rate of adverse events at 30 days was identical. A non-significant reduction of the 72-h AUC for hsTnI (-24%, p = 0.15) was observed when sevoflurane was administered during cardiopulmonary bypass (46% of patients in the treated group). The incidence of postoperative renal failure was not reduced (p = 0.104).

CONCLUSION

This multimodal cardioprotection has not demonstrated any biological or clinical benefit during cardiac surgery. The cardio- and reno-protective effects of sevoflurane and remote ischemic preconditioning therefore remain to be demonstrated in this context.

Для цитирования: Chiari Pascal, Desebbe Olivier, Durand Michel, Fischer Marc-Olivier, Lena-Quintard Diane, Palao Jean-Charles, Samson Géraldine, Varillon Yvonne, Vaz Bernadette, Joseph Pierre, Ferraris Arnaud, Jacquet-Lagreze Matthias, Pozzi Matteo, Maucort-Boulch Delphine, Ovize Michel, Bidaux Gabriel, Mewton Nathan, Fellahi Jean-Luc, ProCCard Trial Investigators. A Multimodal Cardioprotection Strategy During Cardiac Surgery: The ProCCard Study.. Journal of cardiothoracic and vascular anesthesia. 2023. DOI: 10.1053/j.jvca.2023.04.011.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.